-
The FDA has approved the first treatment for relapsed or refractory peripheral T-cell lymphoma. Pralatrexate, an inhibitor of dihydrofolate reductase, was granted accelerated approval by the FDA. It will be marketed by Allos Therapeutics as Folotyn™.
-
The Guttmacher Institute, in collaboration with the World Health Organization, recently published an updated account of abortion rates worldwide.
-
It is not a great mystery that primary ovarian cancer, when presenting with metastatic intra-abdominal and/or extra-abdominal disease, represents a formidable therapeutic challenge, as these women are usually highly symptomatic, frequently of poor nutrition, and in need of aggressive dual modality therapy: surgery and chemotherapy.
-
-
-
A 2009 influenza a (h1n1) vaccine was evaluated in a large randomized placebo controlled study in China. The immunization schedule consisted of two doses administered 21 days apart.
-
Until recently, the literature has offered little direction on how to manage patients who have short cervices in the second trimester.
-
In this issue: Efficacy of once-daily insulin, aldo-sterone use in heart failure, erectile dysfunction Clinical Practice Guidelines, and FDA Actions.
-
Good news for patients at your clinic: The second-generation FC2 Female Condom is available for purchase in the United States, which gives American women a nonlatex, female-controlled option in disease protection.
-
Women in the United States now account for more than one-quarter of all new HIV/AIDS diagnoses.
